Ad
related to: medications for high eosinophils in blood
Search results
Results from the WOW.Com Content Network
Eosinophilia is a condition in which the eosinophil count in the peripheral blood exceeds 5 × 10 8 /L (500/μL). [1] Hypereosinophilia is an elevation in an individual's circulating blood eosinophil count above 1.5 × 10 9 /L (i.e. 1,500/μL).
Hypereosinophilic syndrome is a disease characterized by a persistently elevated eosinophil count (≥ 1500 eosinophils/mm³) in the blood for at least six months without any recognizable cause, with involvement of either the heart, nervous system, or bone marrow.
Chronic eosinophilic pneumonia is most likely when the symptoms have been present for more than a month. Laboratory tests typical of chronic eosinophilic pneumonia include increased levels of eosinophils in the blood, a high erythrocyte sedimentation rate, iron deficiency anemia, and increased platelets. A chest X-ray can show abnormalities ...
Eosinopenia is a condition where the number of eosinophils, a type of white blood cell, in circulating blood is lower than normal. [1] Eosinophils are a type of granulocyte and consequently from the same cellular lineage as neutrophils, basophils, and mast cells.
The symptoms of DRESS syndrome usually begin 2 to 6 weeks but uncommonly up to 8–16 weeks after exposure to an offending drug. Symptoms generally include fever, an often itchy rash which may be morbilliform or consist mainly of macules or plaques, facial edema (i.e. swelling, which is a hallmark of the disease), enlarged and sometimes painful lymph nodes, and other symptoms due to ...
Eosinophilia, increase (>500 cells per microliter) in eosinophil blood count Hypereosinophilia , extreme increase (>1,500 cells per microliter) in eosinophil blood count Clonal hypereosinophilia , presence of a premalignant or malignant clone of eosinophils in bone marrow and blood
It differs from other drug reactions in that it: a) is caused by a particular set of drugs; b) typically occurs after a delay of 2 to 8 weeks following intake of an offending drug; c) presents with a specific set of signs and symptoms (i.e. modest or extreme elevations in blood eosinophil and atypical lymphocyte counts; acute onset of a skin ...
Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma.
Ad
related to: medications for high eosinophils in blood